ASSOCIATION OF CIRCULATING FGF-23 AND KLOTHO WITH CARDIOVASCULAR DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Ayla YILDIZ, Levent DENİZ

The Medical Bulletin of Haseki - 2026;64(4):222-228

University of Health Sciences Türkiye, Basaksehir Cam and Sakura City Hospital, Clinic of Medical Biochemistry, Istanbul, Türkiye

 

Aim: Chronic kidney disease (CKD) contributes to an increased risk of cardiovascular disease (CVD) beyond traditional risk factors, partly through the fibroblast growth factor 23 (FGF-23) and Klotho pathways. This study examined the association between circulating FGF-23 and Klotho levels and CVD in individuals with CKD. Methods: This cross-sectional study included 110 patients with CKD treated at University of Health Sciences Türkiye, Istanbul Haseki Training and Research Hospital. Patients were classified into CVD-positive (n=56) and CVD-negative (n=54) groups according to the presence of CVD, defined as coronary artery disease, ischaemic stroke, or peripheral arterial disease. Serum FGF-23 and Klotho levels were quantified using enzyme-linked immunosorbent assay, and routine biochemical and hormonal parameters were simultaneously assessed. Statistical analyses included group comparisons, correlation analyses, and binary logistic regression. Results: Patients with CVD had higher serum FGF-23 levels than those without CVD (p=0.022), whereas Klotho levels did not differ between the groups. Multivariate regression analyses showed that FGF-23 was associated with CVD [odds ratio =1.0026 (1.0002-1.0049), p=0.032] after adjusting for estimated glomerular filtration rate, age, sex, diabetes mellitus, and hypertension. Klotho showed inverse correlations with creatinine (r=-0.297, p=0.029) in CVD-negative patients and with glucose (r=-0.299, p=0.025) in CVD-positive patients and was positively associated with FGF-23 (r=0.558, p<0.001) in CVD-positive patients. Conclusion: Elevated FGF-23 levels were associated with CVD in patients with CKD, whereas Klotho levels did not distinguish patients with CVD. These findings suggest a possible relationship between FGF-23 and CVD in CKD; however, further studies are required.